Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01273142
Recruitment Status : Unknown
Verified December 2010 by Henan Provincial Hospital.
Recruitment status was:  Not yet recruiting
First Posted : January 10, 2011
Last Update Posted : January 10, 2011
Merck Sharp & Dohme Corp.
Information provided by:
Henan Provincial Hospital

Brief Summary:
The purpose of this study is to demonstrate the difference in frequency and level of liver function disturbance between patients on efavirenz based ART, and patients on nevirapine based ART in HBV and HCV co-infected patients, (and/or with patients with abnormal liver function prior to ART), in China. Liver function tests will be measured at baseline and follow-up.

Condition or disease
HIV Infections Liver Toxicity Hepatitis Co-infection

Detailed Description:
The introduction of highly active antiretroviral therapy (HAART) has led to a significant reduction in AIDS-related morbidity and mortality. However, the frequent occurrence of chronic hepatitis progressing toward cirrhosis and/or hepatocarcinoma has been recognized as an increasing contributor to death of HIV-infected patients since early in the HAART era In China among the estimated 700,000 people living with HIV in China as of 20061, the percentage of HIV/HCV co-infected patients is high at 56.9%2. For these reasons, during HAART scrupulous attention should paid to the patients' liver function. At present, for price consideration, the NNRTI HIV drug used for antiretroviral therapy in China is nevirapine, which may lead to higher potential risk of liver function disturbance in clinical practice than efavirenz4-5.Roberto Manfredi and his colleagues3found that in a NVP treated group, patients showed at least a 2-fold increase of transaminases versus baseline as hepotoxicity index, while in EFV group, the number of patients with hepotoxicity showed a reduction, Also in the same study, time to reach transaminase peak value was shorter in the NVP group, which also demonstrate the liver toxicity side effect in NVP group. Recently some data has also shown an unusually high incidence of liver function disturbance in patients on HIV antiretroviral therapy in China6. Therefore to evaluate frequency and risk of patient hepatotoxicity caused by different HAART regimens in HBV-/HCV- co-infected HIV patients is necessary to provide evidence therapy for what HAART treatment should be used in China.

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective, Open-label 96-week Observational Pilot Study to Compare the Safety of Efavirenz Versus Nevirapine (Each in Combination With Zidovudine and Lamivudine or Tenofovir and Lamivudine) in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection.
Study Start Date : January 2011
Estimated Primary Completion Date : October 2012
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Antiretroviral treatment naive patients with HIV-1 RNA level≥500 copies/ml and with AST or ALT > 2x the upper limit of normal, and TBIL > 1.5x the upper limit of normal.

Inclusion Criteria:

(Patients must meet all of the following criteria to enter this study.)

  • Patients must be >18years of age and < 60 years of age
  • Patients must be antiretroviral naive and have a HIV-1 RNA level≥500 copies/ml
  • Patients with AST or ALT > 2x the upper limit of normal, and TBIL > 1.5x the upper limit of normal
  • CD4 count to be <250 in female patients and <350 in male patients at entry
  • Hemoglobin content to be > 90g/L
  • Neutrophil cell count to be > 0.75 x 109/L
  • Patients must be willing to accept the

Exclusion criteria:

(Patients meeting one or more of the following criteria will not be enrolled in this study.)

  • Patients with allergies to or other contraindications for the selected ARV regimens.
  • AST or ALT > 5x the upper limit of normal
  • TBIL>2.5 x the upper limit of normal
  • TB co-infection and other co-infection
  • Pregnant or breastfeeding women
  • Intravenous drug users
  • Patient's education level that would interfere with the medical, adherence and withdrawal symptoms evaluation.

Responsible Party: Henan Provincial Hospital, Henan Provincial Infectious Disease Hospital Identifier: NCT01273142     History of Changes
Other Study ID Numbers: zzly-37183
First Posted: January 10, 2011    Key Record Dates
Last Update Posted: January 10, 2011
Last Verified: December 2010

Keywords provided by Henan Provincial Hospital:
Human Immunodeficiency Virus, liver toxicity, hapatitis co-infection

Additional relevant MeSH terms:
Communicable Diseases
Hepatitis A
Hepatitis C
HIV Infections
Hepatitis B
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Lentivirus Infections
Retroviridae Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Parasitic Diseases
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors